Endogenous peptide CBDP1 inhibits clear cell renal cell carcinoma progression by targeting USP5/YTHDF2/TRPM5 axis

Abstract Background: Clear cell renal cell carcinoma (ccRCC) has a high incidence rate and poor prognosis, and currently lacks effective therapies. Recently, peptide-based drugs have shown promise in cancer treatment. In this research, a new endogenous peptide called CBDP1 was discovered in ccRCC an...

Cijeli opis

Bibliografski detalji
Glavni autori: Yang Zhang, Wei Zhu, Ruijie Tao, Weijian Li, Chunming Jiang, Xiang Yan
Format: Članak
Jezik:English
Izdano: BMC 2025-01-01
Serija:Journal of Translational Medicine
Teme:
Online pristup:https://doi.org/10.1186/s12967-025-06091-4